Miriam Kidron - Jan 3, 2022 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role: Chief Scientific Officer, Director
Signature: /s/ Miriam Kidron
Stock symbol: ORMP
Transactions as of: Jan 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/5/2022, 07:39 PM
Previous filing: Sep 2, 2021
Next filing: Aug 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ORMP	Common Stock	Award		+42K	+29.65%		184K	Jan 3, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ORMP	Stock Option (right to buy)	Award	$0	+72K		$0.00	72K	Jan 3, 2022	Common Stock	72K	$13.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 10,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2	The Stock Option will vest in 4 installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.